DR. REDDY'S LABORATORIES, INC. et al. vs Novo Nordisk A/S

Termination Decision: Post-DI Settlement

Order: Order on Motions to Expunge

Order: On Protective Orders and Motions to Seal

Decision Granting Institution of Inter Partes Review Granting Motion for Joinder

Patent Owner's Further Authorized Reply

EX2024 - Excerpt of Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.)

EX2025 - Excerpt of Opening Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.)

EX2026 - Excerpt of Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.)

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5

Updated Exhibit List

District Court Order re Trial Date

Proposed Stipulation

Patent Owner's Sur-Reply

Petitioners’ Reply To Patent Owner’s Preliminary Response

Exhibit 3001

EX2001 - Excerpt of Defendants’ Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022)

EX2002 - Petition for Inter Partes Review, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.1 (Mar. 16, 2023)

EX2003 - Declaration of Sayem Osman

EX2004 - Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 245 (D. Del. Oct. 31, 2023)

EX2005 - Nov. 29, 2023 Email from E. Goldschlager to Counsel, re: IPR2023-00724 – Request for Conference Call

EX2006 - Scheduling Order, Novo Nordisk Inc. v. Rio Biopharms., Inc., No. 1:22-cv-00294-CFC, Dkt. 22 (D. Del.)

EX2007 - Excerpt of Transcript of Dec. 13, 2023 Claim Construction Hearing, Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc., No. 23-101-CFC (D. Del. Dec. 13, 2023)

EX2008 - Claim Construction Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 148 (D. Del. July 25, 2023)

EX2009 - Joint Stipulation and Order Amending Scheduling Order, In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-03038-CFC, Dkt. 268 (D. Del. Dec. 1, 2023)

EX2010 - Excerpt of Novo Nordisk’s Second Amended Disclosures to Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc., In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. July 28, 2023)

EX2011 - U.S. Patent No. 8,114,833

EX2012 - Waiver of Service of Summons for Dr. Reddy’s Laboratories, Inc., Novo Nordisk Inc. v. Dr. Reddy’s Lab’ys Ltd., No. 1:22-cv-00298-CFC, Dkt. 6 (D. Del., Mar. 4, 2022)

EX2013 - Waiver of Service of Summons for Dr. Reddy’s Laboratories Ltd., Novo Nordisk Inc. v. Dr. Reddy’s Lab’ys Ltd., No. 1:22-cv-00298-CFC, Dkt. 7 (D. Del. Mar. 4, 2022)

EX2014 - Excerpt of Redacted Patent Owner’s Response, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.30 (Jan. 17, 2023)

EX2015 - Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Dec. 21, 2022)

EX2016 - Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 1 (D. Del. Aug. 5, 2022)

EX2018 - Excerpt of Defendants’ Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Nov. 2, 2023)

EX2019 - Novo Nordisk Production Letter, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED]

EX2020 - Novo Nordisk Production Letter, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED]

EX2021 - Compilation of Rule 30(b)(1) Deposition Notices, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.)

EX2022 - Notice of Service for Defendants’ Initial Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022)

EX2023 - Notice of Service for Defendants’ Supplemental Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Nov. 6, 2023).

Preliminary Response

Joint Stipulation Regarding Petitioners' Motion for Joinder

Order: Conduct of the Proceeding 37 C.F.R. sec. 42.5

Power of Attorney and Designation of Lead and Back-Up Counsel

Patent Owner's Mandatory Notices

Power of Attorney and Designation of Lead and Back-Up Counsel

Patent Owner's Mandatory Notices

Power of Attorney and Designation of Lead and Back-Up Counsel

Patent Owner's Mandatory Notices

Notice: Notice filing date accorded

Petitioners DLR Power of Attorney

U.S. Patent No. 10,335,462

Prosecution history excerpts for U.S. Patent No. 10,335,462

Declaration of John Bantle, MD

CV of John Bantle, MD

Declaration of William J. Jusko, Ph.D.

CV of William J. Jusko, Ph.D.

Declaration of Paul Dalby, Ph.D.

CV of Paul Dalby, Ph.D.

WO 2011/138421

Lovshin, Incretin-Based Therapies for Type 2 Diabetes Mellitus, 5 NATURE RE

Clinical Trial No. NCT00696657

Clinical Trial No. NCT00851773

WO 2006/097537

U.S. Patent Application Pub. No. US2007/0010424

U.S. Patent No. 5,512,549

Banting, The Internal Secretion of the Pancreas, 7 J. LAB. CLINICAL MED. 25

Bell, Hamster Preproglucagon 302 NATURE 716 (1983)

Bydureon prescribing information (Jan. 2012)

Byetta prescribing information (Oct. 2009)

Drab, Incretin-Based Therapies for Type 2 Diabetes PHARMA 609 (2010)

Drucker, Enhancing Incretin Action 26 DIABETES CARE 2929 (2003)

Drucker, The Incretin System, 368 LANCET 1696 (2006)

Glaesner, Engineering, 26 DIABETES/METABOLISM RSCH. & REV. 287 (2010)

HARRISON’S PRINCIPLES OF INTERNAL MED., 338 (Fauci 17th eds. 2008)

Holst, Truncated Glucagon-like Peptide I, 211 (2) FEBS LETTERS 169 (1987)

Holst, Glucagon-Like Peptide 1, CURRENT OP. IN PHARMACOLOGY 589 (2004)

Jimenez-Solem, Dulaglutide, 12 current OP. in Molecular Therap. 90 (2010)

Kim, Effects of Once-Weekly Dosing, 30 DIABETES CARE 1487 (2007)

Knudsen, GLP-1 Derivatives, 26 DRUGS OF THE FUTURE 677 (2001)

Knudsen, Glucagon-like Peptide-1, 47 J. MED. CHEMISTRY 4128 (2004)

Knudsen, Liraglutide, Analogue-Based Drug (Fischer & Ganellin 2010)

U.S. Patent No. 6,268,343

Lund, Emerging GLP-1 Receptor, 6 EXPERT OP. ON EMERGING DRUGS 607 (2011)

Mojsov, Insulinotropin,79 J. CLINICAL INVESTIGATION 616 (1987)

Nielsen, Pharmacology of Exenatide, 117 REGUL. PEPTIDES 77 (2004)

Seino, Dose-Dependent, 81 DIABETES RSCH. & CLINICAL PRACTICE 161 (2008)

Victoza, PHYSICIANS’ DESK REFERENCE (65th ed. 2010)

Vilsbøll, Glucagon-Like Peptide-1, INT’L DIABETES MONITOR 1 (2009)

WO 03/002136

WO 91/11457

U.S. Patent App. Pub. 2004/0102486

Rohatagi, Model-Based Development, 48 J. CLINICAL PHARMACOLOGY 1420 (2008)

Shargel, APPLIED BIOPHARMACEUTICS & PHARMACOKINETICS (5th ed. 2005)

Yun, Pharmacokinetic, 31 J. CLINICAL PHARMACY & THERAPEUTICS 469 (2006)

Tamimi, Drug Development, 13 NEPHRON CLINICAL PRACTICE c125 (2009)

FDA Guidance for Industry, Analysis, and Regulatory Applns. (Apr. 2003)

Int'l Conf. on Harmonisation, 59 Fed. Reg. 55972 (Nov. 9, 1994

Garber, Efficacy of Metformin in Type II Diabetes,102 J.MED. 491 1997

Landersdorfer, Pharmacokinetic (47(7) CLINICAL PHARMACOKINETICS 417 (2008)

Madsbad, An Overview, 13 DIABETES, OBESITY & METABOLISM 394 (2011)

Møller, Mechanism-Based, 38 J. PHARMACOKINETICS 713 (2011)

Landersdorfer, Mechanism-Based,73 BRIT. J. CLINICAL PHARMACOLOGY 391 (2011)

Landersdorfer, Mechanism-Based 73 BRIT. J. CLINICAL PHARMACOLOGY 373 (2011)

U.S. Patent No. 5,118,666

WO 2011/073328

Blonde, Comparison of Liraglutide(suppl. 2) DIABETES, OBES, & METAB. 2012

Murphy, Review of the Safety, 46 ANNALS OF PHARMACOTHERAPY 812 (2012)

WO 2011/058193

U.S. Patent App. Pub. No. 2011/0166321

Zarin, The ClinicalTrials.gov Results Data, 364 NEW ENGL. J. MED. 852 2011

Kirillova, Results and Outcome,7(6) PLOS ONE 1 (2012)

Monami, Effects of Glucagon-Like Peptide-1 EXPER. DIABETES RSCH. 1 (2012)

Tasneem, The Database for Aggregate Analysis,7(3) PLOS ONE 1(2012)

Knudsen, Liraglutide, INT’L J. CLINICAL PRACTICE 4 (2010)

U.S. Patent No. 8,536,122

U.S. Patent No. 8,129,343

REMINGTON, THE SCIENC&PRACTICE, Alfonso R. Gennaro ed., 20th ed. 2000

Boylan, Parenteral Products, Gilbert S. Banker et al. eds., 3d ed. 1996

U.S. Patent No. 6,284,727

U.S. Patent No. 5,164,366

U.S. Patent No. 6,458,924

WO 00/37098

U.S. Patent No. 7,022,674

ClinicalTrials.gov Background, CLINICALTRIALS.GOV

Award: ClinicalTrials.gov

U.S. Patent App. Pub. No. 2004/0102486

NCT00167115, CLINICALTRIALS.GOV

NCT01933490, CLINICALTRIALS.GOV

Ozempic prescribing information (Oct. 2022)

Scheduling Order, No. 22-294 (CFC), D. Del. June 30, 2022, ECF No. 22

Transfer Order, In re: Ozempic, No. 3038 (MDL Aug. 5, 2022)

EMA, ICH Topic S 7 A Safety Pharma. Studies for Human Pharma. June 2001

ACS Publications

“Last Update Posted” definition from ClinicalTrials.gov

Prosecution history excerpts for U.S. Patent No. 9,764,003

Declaration of Dr. Russell M. Zusman

CV of Dr. Russell M. Zusman

Declaration of Dr. John P. Fruehauf

CV of Dr. John P. Fruehauf

Declaration of Dr. Maureen M. Donovan

CV of Dr. Maureen M. Donovan

Mylan Pharma. Inc., v. Novo Nordisk IPR2023-00724, Paper 10, Oct. 4, 2023

Markman Hearing Transpt. Re: OzempicNo. 22-MD-3038 (D. Del. July 13, 2023)

Claim Construction Order, No. 22-MD-3038 (D. Del. July 25, 2023), ECF 148

Joint Claim Construction Brief, No. 22-MD-3038 D.Del. May 1, 2023), ECF 119

IPR Petition DRL '462

Motion : DLR '462 PETITIONERS’ MOTION FOR JOINDER